Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer

(2018) Michal Sarfaty et al.   EUROPEAN UROLOGY

Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer

(2018) David J. Vaughn et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

(2018) Thomas Powles et al.   LANCET

Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer

(2018) Daniel P. Petrylak et al.   JAMA Oncology

Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210.

(2018) Arjun Vasant Balar et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer

(2017) J. Alfred Witjes et al.   EUROPEAN UROLOGY

Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study

(2017) Elizabeth R Plimack et al.   LANCET ONCOLOGY

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

(2017) Padmanee Sharma et al.   LANCET ONCOLOGY

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

(2017) Joaquim Bellmunt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

(2017) Thomas Powles et al.   JAMA Oncology

Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy

(2016) N. Houédé et al.   BMC CANCER

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

(2016) Padmanee Sharma et al.   LANCET ONCOLOGY

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

(2016) Tanguy Y Seiwert et al.   LANCET ONCOLOGY

Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up

(2014) J. Bellmunt et al.   ANNALS OF ONCOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER